Post-Approval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States–Based Rheumatoid Arthritis Registry
ACR Open Rheumatol. 2021 Feb 11.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
ACR Open Rheumatol. 2021 Feb 11.
Annals of the rheumatic diseases. 2021 Mar 1;80(3):312-20.
Please click the links below to go to the CSF review of each paper
RMD Open 2020;6:e001374 doi:10.1136/rmdopen-2020-001374
Ann Rheum Dis 2020 DOI:10.1136/annrheumdis-2020-218510
Annals of the Rheumatic Diseases, May 2020
Annals of the Rheumatic Diseases 2020;79:760-770
Rheumatol Ther 2020 doi.org/10.1007/s40744-020-00209-4
Lancet Rheumatol 2020;2:e347–57
Drug Saf. 2020;43:379-392